1. Home
  2. |Insights
  3. |Litigation Note: Crowell & Moring Secures IP Victory for Watson Pharmaceuticals (now Actavis)

Litigation Note: Crowell & Moring Secures IP Victory for Watson Pharmaceuticals (now Actavis)

Firm News | less than 1 min read | 04.15.13

Washington, D.C. – April 15, 2013: Crowell & Moring represented Watson Pharmaceuticals, Inc. (now Actavis, Inc.) in successfully defending the patent infringement case brought by Bayer HealthCare Pharmaceuticals Inc. regarding its RE37,564 patent for the Yaz ® contraceptive. Today, the Federal Circuit reversed the adverse summary judgment decision made by the district court in March 2012 and held that Bayer's asserted patent claims were invalid. The court found that the cited prior art references set forth every limitation required by the asserted claims and provide express motivation to combine those teachings to derive the claimed oral contraceptive product. As a result of the decision today, Actavis has re-launched its generic product.


Insights

Firm News | 1 min read | 02.18.26

Crowell & Moring Shortlisted for Two Litigation of the Year Honors at the Global Competition Review Awards

Washington, D.C. – February 18, 2026: Crowell & Moring has been shortlisted for two honors at the 2026 Global Competition Review (GCR) Awards, both in the Litigation of the Year – Cartel Defense category. The GCR Awards recognizes the world’s leading antitrust lawyers, economists, and enforcers, and highlights the most significant cases from 2025....